Abstract Details

Title Effects of HIV Clade B and C on Brain Volumetric Measurements

Topic Infections/AIDS/Prion Disease

Presentation(s) P06 - (-)

Poster/Presentation
Number 177

Objective

Background BACKGROUND: HIV type 1 has genetic subtypes (clades) with varying prevalence throughout the world. [1] Previous in-vitro and animal research studies that have compared HIV-1B and HIV-1C have suggested that HIV-1B may be more neurovirulent than HIV-1C. While recent clinical studies have shown that a high frequency of cognitive impairment is evident in both clades, no studies have directly compared brain volumetric indices.

Design/Methods DESIGN/METHODS: 68 age- and education-matched participants (17 HIV-1C combination anti-retroviral therapy (cART) naive, 17 HIV-1B cART naive, and 17 HIV-negative controls from each region) were recruited from the US (HIV-1B) and South Africa (HIV-1C). All subjects underwent laboratory studies, and neuroimaging performed on Siemens 3T scanners with identical sequence parameters. Nine a priori volumetric regions were analyzed from Freesurfer v5.1; (caudate, thalamus, hippocampus, corpus callosum, putamen, grey and white matter, total ventricular volume and amygdala). The impact of clade was evaluated by the interaction term in a factorial two-way ANOVA with HIV status and group (clade) as factors. Additionally, lower HIV-1C counts are associated with smaller caudate volume.

Results RESULTS: HIV infected (HIV+) individuals in general had smaller volumes in thalamus and global grey matter, compared to HIV- controls. HIV-1C and HIV-1B individuals displayed a similar degree of atrophy compared to HIV- controls within the various regions analyzed. When accounting for duration of infection, HIV-1C had a larger amount of atrophy in total grey matter (2.7% greater loss in HIV-1C than HIV-1B; p= .02).

Conclusions CONCLUSIONS: Although in-vitro studies suggest HIV-1B may be more neurotoxic, we did not see the same trend in our clade B to clade C comparison. Future longitudinal studies are required to assess the effects of cART on volumetric measures within these clades.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Beau M. Ances, MD, PhD, MS, FAAN (Washington University in Saint Louis)	Dr. Ances has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH.
Aaron E. Miller, MD, FAAN (Mt Sinai School Of Med)	Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Accordant Health Services (Caremark). Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Corevitas (formerly known as Corrona). Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for MAPI=Pharma. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Viatris (Mylan). Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Guidepoint Global. Dr. Miller has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen Idec. Dr. Miller has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Miller has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen (Horizon Therapeutics). Dr. Miller has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Sterne Kessler. Dr. Miller has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��